2017
DOI: 10.1016/j.cyto.2016.12.003
|View full text |Cite
|
Sign up to set email alerts
|

Liver X receptors agonists suppress NLRP3 inflammasome activation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
12
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 42 publications
1
12
0
Order By: Relevance
“…ILG-mediated suppression of NLRP3 and down-regulation of caspase-1 and IL-1β activation has also been reported [ 166 ]. Similar results were reported for SFN, two liver X receptors T0901317 and GW3965, and Spirodalesol [ 167 , 168 , 169 ]. Recently, the ketone body β-hydroxybutyrate (BHB) and MCC950 were revealed to specifically inhibit inflammasome activation.…”
Section: Major Therapeutic Strategies For Hepatocarcinogenesissupporting
confidence: 86%
“…ILG-mediated suppression of NLRP3 and down-regulation of caspase-1 and IL-1β activation has also been reported [ 166 ]. Similar results were reported for SFN, two liver X receptors T0901317 and GW3965, and Spirodalesol [ 167 , 168 , 169 ]. Recently, the ketone body β-hydroxybutyrate (BHB) and MCC950 were revealed to specifically inhibit inflammasome activation.…”
Section: Major Therapeutic Strategies For Hepatocarcinogenesissupporting
confidence: 86%
“…However, under certain conditions, when “inflammatory machinery” is not properly orchestrated, inflammation may lead to significant pathology. The pathogenic role of inflammasome in many types of liver disease is well documented [141,142]. For instance, the NLRP3 inflammasomes, activated by telomere-independent repressor activator protein 1 (RAP1)/keratinocyte chemoattractant axis, played a critical role in initiating inflammation during the early stage of liver graft injury.…”
Section: Relevance Of Inflammasome In Hepatic Ischemia-reperfusionmentioning
confidence: 99%
“…Furthermore, two liver X receptors T0901317 and GW3965 were identified to potently inhibit NLRP3 inflammasome activation, which was accomplished by the reduction of inflammasome-associated mtROS production, ASC oligomerization, casp1 cleavage, and IL-1β secretion. Additionally, these agonists suppressed the priming signaling of NLRP3 inflammasome activation ( 65 ). Besides, a unique mode of action in inhibiting NLRP3 inflammasome activation was recently described by Zhang et al, who found that spirodalesol repressed NLRP3 inflammasome assembly, while displayed neither inhibition of p65 activation and luciferase activity of NF-κB nor IL-1β mRNA levels in BMDMs, suggesting that spirodalesol selectively blocked signal II but not signal I of NLRP3 inflammasome activation ( 66 ).…”
Section: Pharmacological Inhibitors Of the Nlrp3 Inflammasomementioning
confidence: 99%